WA43966: A Phase III Multicenter Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of RO7434656 An Antisense Inhibitor of Complement Factor B in Patients with Primary IgA Nephropathy at High Risk of Progression

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Clinical Research Studies

WA43966: A Phase III Multicenter Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of RO7434656 An Antisense Inhibitor of Complement Factor B in Patients with Primary IgA Nephropathy at High Risk of Progression

Recruitment Status

Contact the research team to learn more about this study.

Recruitment Status

212-263-4432

646-754-7432